Roles of APOBEC3 in hepatitis B virus (HBV) infection and hepatocarcinogenesis

References

• Silvas TV, Schiffer CA. APOBEC3s: DNA-editing human cytidine deaminases. Protein Sci. 2019;28(9):1552–1566.
   PubMed Web of Science ®Google Scholar
• Knisbacher BA, Gerber D. Levanon EY: DNA editing by APOBECs: a genomic preserver and transformer. Trends Genet. 2016;32(1):16–28.
   PubMed Web of Science ®Google Scholar
• Revathidevi S, Murugan AK, Nakaoka H, et al. Munirajan AK: APOBEC: a molecular driver in cervical cancer pathogenesis. Cancer Lett. 2021;496:104–116.
   PubMed Web of Science ®Google Scholar
• Hultquist JF, Lengyel JA, Refsland EW, et al. Harris RS: human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict vif-deficient HIV-1. J Virol. 2011;85(21):11220–11234.
   PubMed Web of Science ®Google Scholar
• Schmitt K, Guo K, Algaier M, et al. Stephens EB: differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution. Virology. 2011;419(1):24–42.
   PubMed Web of Science ®Google Scholar
• Virgen CA. Hatziioannou T: antiretroviral activity and vif sensitivity of rhesus macaque APOBEC3 proteins. J Virol. 2007;81(24):13932–13937.
   PubMed Web of Science ®Google Scholar
• Harris RS. Dudley JP: aPOBECs and virus restriction. Virology. 2015;479-480:131–145.
   PubMed Web of Science ®Google Scholar
• Stavrou S. Ross SR: APOBEC3 Proteins in viral immunity. J Immunol. 2015;195(10):4565–4570.
   PubMed Web of Science ®Google Scholar
• Bouzidi MS, Caval V, Suspene R, et al. Vartanian JP: APOBEC3DE antagonizes Hepatitis B Virus restriction factors APOBEC3F and APOBEC3G. J Mol Biol. 2016;428(17):3514–3528.
   PubMed Web of Science ®Google Scholar
• Poulain F, Lejeune N, Willemart K. Gillet NA: footprint of the host restriction factors APOBEC3 on the genome of human viruses. PLoS Pathog. 2020;16(8):e1008718.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wakae K, Kitamura K, et al. Muramatsu M: APOBEC3 deaminases induce hypermutation in human papillomavirus 16 DNA upon beta interferon stimulation. J Virol. 2014;88(2):1308–1317.
   PubMed Web of Science ®Google Scholar
• Milewska A, Kindler E, Vkovski P, et al. Pyrc K: APOBEC3-mediated restriction of RNA virus replication. Sci Rep. 2018;8(1):5960.
   PubMed Web of Science ®Google Scholar
• Bieniasz PD. Intrinsic immunity: a front-line defense against viral attack. Nat Immunol. 2004;5(11):1109–1115.
   PubMed Web of Science ®Google Scholar
• Kinomoto M, Kanno T, Shimura M, et al. Tokunaga K: all APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res. 2007;35(9):2955–2964.
   PubMed Web of Science ®Google Scholar
• Okada A. Iwatani Y: APOBEC3G-Mediated G-to-A hypermutation of the HIV-1 genome: the missing Link in antiviral molecular mechanisms. Front Microbiol. 2016;7:2027.
   PubMed Web of Science ®Google Scholar
• Aydin H, Taylor MW. Lee JE: structure-guided analysis of the human APOBEC3-HIV restrictome. Structure. 2014;22(5):668–684.
   PubMed Web of Science ®Google Scholar
• Suspene R, Henry M, Guillot S, et al. Vartanian JP: recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR. J Gen Virol. 2005;86(Pt 1):125–129.
   PubMed Web of Science ®Google Scholar
• Bobrovnitchaia I, Valieris R, Drummond RD, et al. da silva IT: APOBEC-mediated DNA alterations: a possible new mechanism of carcinogenesis in EBV-positive gastric cancer. Int J Cancer. 2020;146(1):181–191.
   PubMed Web of Science ®Google Scholar
• Borzooee F, Asgharpour M, Quinlan E, et al. Larijani M: viral subversion of APOBEC3s: lessons for anti-tumor immunity and tumor immunotherapy. Int Rev Immunol. 2018;37(3):151–164.
   PubMed Web of Science ®Google Scholar
• Koito A. Ikeda T: intrinsic immunity against retrotransposons by APOBEC cytidine deaminases. Front Microbiol. 2013;4:28.
   PubMed Web of Science ®Google Scholar
• Nowarski R, Wilner OI, Cheshin O, et al. APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. Blood. 2012;120(2):366–375.
   PubMed Web of Science ®Google Scholar
• Starrett GJ, Luengas EM, McCann JL, et al. The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. Nat Commun. 2016;7:12918.
   PubMed Web of Science ®Google Scholar
• Suspene R, Mussil B, Laude H, et al. Vartanian JP: self-cytoplasmic DNA upregulates the mutator enzyme APOBEC3A leading to chromosomal DNA damage. Nucleic Acids Res. 2017;45(6):3231–3241.
   PubMed Web of Science ®Google Scholar
• Burns MB, Temiz NA. Harris RS: evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013;45(9):977–983.
   PubMed Web of Science ®Google Scholar
• Roberts SA, Lawrence MS, Klimczak LJ, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45(9):970–976.
   PubMed Web of Science ®Google Scholar
• He X, Xu H, Wang X, et al. Gao P: associations between the single nucleotide polymorphisms of APOBEC3A, APOBEC3B and APOBEC3H, and chronic hepatitis B progression and hepatocellular carcinoma in a Chinese population. Mol Med Rep. 2019;20(3):2177–2188.
   PubMed Web of Science ®Google Scholar
• Mas-Ponte D. Supek F: DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers. Nat Genet. 2020;52(9):958–968.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Burns MB, Lackey L, Carpenter MA, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013;494(7437):366–370.
   PubMed Web of Science ®Google Scholar
• Leonard B, Hart SN, Burns MB, et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 2013;73(24):7222–7231.
   PubMed Web of Science ®Google Scholar
• Vartanian JP, Henry M, Marchio A, et al. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog. 2010;6(5):e1000928.
   PubMed Web of Science ®Google Scholar
• Yang Z, Lu Y, Xu Q, et al. Chen X: correlation of APOBEC3 in tumor tissues with clinico-pathological features and survival from hepatocellular carcinoma after curative hepatectomy. Int J Clin Exp Med. 2015;8(5):7762–7769.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhuang L, Yu Y, et al. Chen X: overexpression of APOBEC3F in tumor tissues is potentially predictive for poor recurrence-free survival from HBV-related hepatocellular carcinoma. Discov Med. 2015;20(112):349–356.
   PubMed Web of Science ®Google Scholar
• Green AM. Weitzman MD: the spectrum of APOBEC3 activity: from anti-viral agents to anti-cancer opportunities. DNA Repair (Amst). 2019;83:102700.
   PubMed Web of Science ®Google Scholar
• Bonvin M, Achermann F, Greeve I, et al. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology. 2006;43(6):1364–1374.
   PubMed Web of Science ®Google Scholar
• Song ZW, Ma YX, Fu BQ, et al. Antibiotic resistance surveillance program in Portugal P: altered mRNA levels of MOV10, A3G, and IFN-alpha in patients with chronic hepatitis B. J Microbiol. 2014;52(6):510–514.
   PubMed Web of Science ®Google Scholar
• Mohamadkhani A, Pourdadash A, Tayebi S, et al. Poustchi H: the potential role of APOBEC3G in limiting replication of hepatitis B virus. Arab J Gastroenterol. 2012;13(4):170–173.
   PubMedGoogle Scholar
• Chen H, Wang LW, Chu XG, et al. Gong ZJ: [expression and subcellular localization of APOBEC3G in peripheral blood mononuclear cells and liver tissues of chronic HBV patients]. Zhonghua Gan Zang Bing Za Zhi. 2010;18(1):5–8.
   PubMedGoogle Scholar
• Meier MA, Suslov A, Ketterer S, et al. Wieland SF: hepatitis B virus covalently closed circular DNA homeostasis is independent of the lymphotoxin pathway during chronic HBV infection. J Viral Hepat. 2017;24(8):662–671.
   PubMed Web of Science ®Google Scholar
• Tsuge M, Noguchi C, Akiyama R, et al. G to A hypermutation of TT virus. Virus Res. 2010;149(2):211–216.
   PubMed Web of Science ®Google Scholar
• Ni L, Li C. Li Y: correlation of APOBEC3G expression with liver function indexes of patients with chronic hepatitis B and comparison in chronic hepatitis B, liver cirrhosis and liver cancer. Oncol Lett. 2020;19(3):2562–2567.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhuang L, Lu Y, et al. Chen X: naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis. Oncotarget. 2016;7(11):12525–12536.
   PubMedGoogle Scholar
• Lau KCK, Joshi SS, Mahoney DJ, et al. Coffin CS: differences in HBV replication, APOBEC3 family expression, and inflammatory cytokine levels between wild-type HBV and pre-core (G1896A) or basal core promoter (A1762T/G1764A) mutants. Front Microbiol. 2020;11:1653.
   PubMed Web of Science ®Google Scholar
• Luo X, Huang Y, Chen Y, et al. Hu Y: association of Hepatitis B Virus covalently closed circular DNA and human APOBEC3B in Hepatitis B Virus-related hepatocellular carcinoma. PLoS One. 2016;11(6):e0157708.
   PubMed Web of Science ®Google Scholar
• Xu R, Zhang X, Zhang W, et al. Yu XF: association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma. Hepatology. 2007;46(6):1810–1820.
   PubMed Web of Science ®Google Scholar
• Yang Z, Tao Y, Xu X, et al. Ma L: bufalin inhibits cell proliferation and migration of hepatocellular carcinoma cells via APOBEC3F induced intestinal immune network for IgA production signaling pathway. Biochem Biophys Res Commun. 2018;503(3):2124–2131.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhu X, Xu W, et al. Peng L: IFNA2 p.Ala120Thr impairs the inhibitory activity of interferon-alpha2 against the hepatitis B virus through altering its binding to the receptor. Antiviral Res. 2017;147:11–18.
   PubMed Web of Science ®Google Scholar
• Ying S, Zhang X, Sarkis PT, et al. Yu X: cell-specific regulation of APOBEC3F by interferons. Acta Biochim Biophys Sin (Shanghai). 2007;39(4):297–304.
   PubMed Web of Science ®Google Scholar
• Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343(6176):1221–1228.
   PubMed Web of Science ®Google Scholar
• Jost S, Turelli P, Mangeat B, et al. Trono D: induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virol. 2007;81(19):10588–10596.
   PubMed Web of Science ®Google Scholar
• Wang JJ, Zhao P, Jin XY, et al. Wu L: expression and the clinical significance of apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G (APOBEC3G) in peripheral blood mononuclear cell of patients with chronic hepatitis B. Chinese Journal of Experimental and Clinical Infectious Diseases (Electronic Edition). 2018;12(1):56–60.
   Google Scholar
• Proto S, Taylor JA, Chokshi S, et al. Naoumov NV: APOBEC and iNOS are not the main intracellular effectors of IFN-gamma-mediated inactivation of Hepatitis B virus replication. Antiviral Res. 2008;78(3):260–267.
   PubMed Web of Science ®Google Scholar
• Furutani Y, Toguchi M, Shiozaki-Sato Y, et al. An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes. PLoS One. 2019;14(6):e0216139.
   PubMed Web of Science ®Google Scholar
• Xia Y, Stadler D, Lucifora J, et al. Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016;150(1):194–205.
   PubMed Web of Science ®Google Scholar
• Block TM. Guo JT: the covalently closed circular form of Hepatitis B Virus genome: is there now an end in “site”?. Gastroenterology. 2016;150(1):34–36.
   PubMed Web of Science ®Google Scholar
• Turelli P, Liagre-Quazzola A, Mangeat B, et al. Trono D: APOBEC3-independent interferon-induced viral clearance in hepatitis B virus transgenic mice. J Virol. 2008;82(13):6585–6590.
   PubMed Web of Science ®Google Scholar
• Koh S, Kah J, Tham CYL, et al. Nonlytic lymphocytes engineered to express virus-specific T-cell receptors limit HBV infection by activating APOBEC3. Gastroenterology. 2018;155(1):180–193 e186.
   PubMed Web of Science ®Google Scholar
• Abe H, Ochi H, Maekawa T, et al. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection. Hepatol Res. 2009;39(12):1159–1168.
   PubMed Web of Science ®Google Scholar
• Gonzalez MC, Suspene R, Henry M, et al. Vartanian JP: human APOBEC1 cytidine deaminase edits HBV DNA. Retrovirology. 2009;6:96.
   PubMed Web of Science ®Google Scholar
• Renard M, Henry M, Guetard D, et al. Wain-Hobson S: APOBEC1 and APOBEC3 cytidine deaminases as restriction factors for hepadnaviral genomes in non-humans in vivo. J Mol Biol. 2010;400(3):323–334.
   PubMed Web of Science ®Google Scholar
• Lei YC, Hao YH, Zhang ZM, et al. Yang DL: inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo. World J Gastroenterol. 2006;12(28):4492–4497.
   PubMed Web of Science ®Google Scholar
• Lei YC, Ma T, Hao YH, et al. Yang DL: [inhibition of hepatitis B and duck hepatitis B virus replication by APOBEC3G]. Zhonghua Gan Zang Bing Za Zhi. 2006;14(10):738–741.
   PubMedGoogle Scholar
• Turelli P, Mangeat B, Jost S, et al. Trono D: inhibition of hepatitis B virus replication by APOBEC3G. Science. 2004;303(5665):1829.
   PubMed Web of Science ®Google Scholar
• Baumert TF, Rosler C, Malim MH. von Weizsacker F: hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology. 2007;46(3):682–689.
   PubMed Web of Science ®Google Scholar
• Suspene R, Guetard D, Henry M, et al. Vartanian JP: extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A. 2005;102(23):8321–8326.
   PubMed Web of Science ®Google Scholar
• Li Y, Xia Y, Han M, et al. Ning Q: IFN-alpha-mediated base excision repair pathway correlates with antiviral response against Hepatitis B Virus infection. Sci Rep. 2017;7(1):12715.
   PubMed Web of Science ®Google Scholar
• Xia Y, Lucifora J, Reisinger F, et al. Protzer U: virology. Response to comment on “specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA”. Science. 2014;344(6189):1237.
   PubMed Web of Science ®Google Scholar
• Lei YC, Tian YJ, Ding HH, et al. Yang DL: n-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication. World J Gastroenterol. 2006;12(46):7488–7496.
   PubMed Web of Science ®Google Scholar
• Kanagaraj A, Sakamoto N, Que L, et al. Kitamura K: different antiviral activities of natural APOBEC3C, APOBEC3G, and APOBEC3H variants against hepatitis B virus. Biochem Biophys Res Commun. 2019;518(1):26–31.
   PubMed Web of Science ®Google Scholar
• Migita K, Abiru S, Ohtani M, et al. HLA-DP gene polymorphisms and hepatitis B infection in the Japanese population. Transl Res. 2012;160(6):443–444.
   PubMed Web of Science ®Google Scholar
• Ezzikouri S, Kitab B, Rebbani K, et al. Benjelloun S: polymorphic APOBEC3 modulates chronic hepatitis B in Moroccan population. J Viral Hepat. 2013;20(10):678–686.
   PubMed Web of Science ®Google Scholar
• Henry M, Guetard D, Suspene R, et al. Vartanian JP: genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS One. 2009;4(1):e4277.
   PubMed Web of Science ®Google Scholar
• Rosler C, Kock J, Kann M, et al. von Weizsacker F: APOBEC-mediated interference with hepadnavirus production. Hepatology. 2005;42(2):301–309.
   PubMed Web of Science ®Google Scholar
• Noguchi C, Ishino H, Tsuge M, et al. Chayama K: g to A hypermutation of hepatitis B virus. Hepatology. 2005;41(3):626–633.
   PubMed Web of Science ®Google Scholar
• Gunther S, Sommer G, Plikat U, et al. Meyerhans A: naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G–>A hypermutation. Virology. 1997;235(1):104–108.
   PubMed Web of Science ®Google Scholar
• Beggel B, Munk C, Daumer M, et al. Erhardt A: full genome ultra-deep pyrosequencing associates G-to-A hypermutation of the hepatitis B virus genome with the natural progression of hepatitis B. J Viral Hepat. 2013;20(12):882–889.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang X, Tian C, et al. Xu R: cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell Microbiol. 2008;10(1):112–121.
   PubMed Web of Science ®Google Scholar
• Bonvin M. Greeve J: hepatitis B: modern concepts in pathogenesis–APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus. Curr Opin Infect Dis. 2008;21(3):298–303.
   PubMed Web of Science ®Google Scholar
• Nguyen DH, Gummuluru S. Hu J: deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol. 2007;81(9):4465–4472.
   PubMed Web of Science ®Google Scholar
• Kitamura K, Wang Z, Chowdhury S, et al. Muramatsu M: uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA. PLoS Pathog. 2013;9(5):e1003361.
   PubMed Web of Science ®Google Scholar
• Zhao D, Wang X, Lou G, et al. APOBEC3G directly binds hepatitis B virus core protein in cell and cell free systems. Virus Res. 2010;151(2):213–219.
   PubMed Web of Science ®Google Scholar
• King JJ. Larijani M: a novel regulator of Activation-Induced Cytidine Deaminase/APOBECs in immunity and cancer: schrodinger’s CATalytic pocket. Front Immunol. 2017;8:351.
   PubMed Web of Science ®Google Scholar
• Rebhandl S, Huemer M, Greil R. Geisberger R: AID/APOBEC deaminases and cancer. Oncoscience. 2015;2(4):320–333.
   PubMedGoogle Scholar
• Swanton C, McGranahan N, Starrett GJ. Harris RS: APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 2015;5(7):704–712.
   PubMed Web of Science ®Google Scholar
• Chan K. Gordenin DA: clusters of multiple mutations: incidence and molecular mechanisms. Annu Rev Genet. 2015;49:243–267.
   PubMed Web of Science ®Google Scholar
• Nik-Zainal S, Alexandrov LB, Wedge DC, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149(5):979–993.
   PubMed Web of Science ®Google Scholar
• Olson ME, Harris RS. Harki DA: APOBEC Enzymes as targets for Virus and cancer therapy. Cell Chem Biol. 2018;25(1):36–49.
   PubMed Web of Science ®Google Scholar
• Chan K, Roberts SA, Klimczak LJ, et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet. 2015;47(9):1067–1072.
   PubMed Web of Science ®Google Scholar
• Cescon DW, Haibe-Kains B. Mak TW: APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc Natl Acad Sci U S A. 2015;112(9):2841–2846.
   PubMed Web of Science ®Google Scholar
• Sieuwerts AM, Willis S, Burns MB, et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer. 2014;5(6):405–413.
   PubMed Web of Science ®Google Scholar
• Vlachostergios PJ. Faltas BM: treatment resistance in urothelial carcinoma: an evolutionary perspective. Nat Rev Clin Oncol. 2018;15(8):495–509.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Moazeni-Roodi A. Taheri M: association of APOBEC3 deletion with cancer risk: a meta-analysis of 26 225 cases and 37 201 controls. Asia Pac J Clin Oncol. 2019;15(6):275–287.
   PubMed Web of Science ®Google Scholar
• Liu W, Wu J, Yang F, et al. Genetic polymorphisms predisposing the interleukin 6-induced APOBEC3B-UNG imbalance increase HCC risk via promoting the generation of APOBEC-Signature HBV mutations. Clin Cancer Res. 2019;25(18):5525–5536.
   PubMed Web of Science ®Google Scholar